Abstract
O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Central Nervous System Agents in Medicinal Chemistry
Title:The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Volume: 12 Issue: 3
Author(s): John C. Ashton
Affiliation:
Keywords: Abnormal Cannabidiol, Cannabidiol, Cannabinoid, inflammation, GPR18, GPR55, O-1602, microglia.
Abstract: O-1602 is a cannabidiol analogue that does not bind with high affinity to either the cannabinoid CB1 receptor or CB2 receptor. However, there is evidence that O-1602 has significant effects in the central nervous system as well as other parts of the body. Depending upon the model, O-1602 has anti-inflammatory or pronociceptive effects, mediated through a number of distinct receptors. This article reviews the evidence for functional effects of O-1602, particularly in the CNS, and describes its known targets as they relate to these effects. These include the abnormal cannabidiol (Abn- CBD) receptor and GPR55. The GPR18 receptor has been identified with the Abn-CBD receptor, and therefore the evidence that O-1602 also acts at GPR18 is also reviewed. Finally, the evidence that these receptor targets are expressed in the CNS and the phenotypes of cells expressing these targets is discussed, concluding with a discussion of the prospects for O-1602 as a therapeutic agent in the CNS.
Export Options
About this article
Cite this article as:
C. Ashton John, The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System, Central Nervous System Agents in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/187152412802430156
DOI https://dx.doi.org/10.2174/187152412802430156 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Studies of Antioxidant Quinoline Derivatives
Mini-Reviews in Medicinal Chemistry Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
Current Drug Targets Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Current Pharmaceutical Design Activated Protein C and Acute Kidney Injury: Selective Targeting of PAR-1
Current Drug Targets Neuroinflammatory Markers in Spontaneously Hypertensive Rat Brain: An Immunohistochemical Study
CNS & Neurological Disorders - Drug Targets Amyloid-like Fibril Formation by Trypsin in Aqueous Ethanol. Inhibition of Fibrillation by PEG
Protein & Peptide Letters Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Clinical Management of Diabetes Mellitus in the Older Adult Patient
Current Diabetes Reviews VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets Targeting New Pharmacological Approaches for Alzheimer’s Disease: Potential for Statins and Phosphodiesterase Inhibitors
CNS & Neurological Disorders - Drug Targets Role of Mitochondrial Heat-shock Proteins and Immunophilins in Neuro Degenerative Diseases
Current Drug Targets Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
Current Pharmaceutical Biotechnology Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Understanding the Multifaceted Role of Inflammatory Mediators in Ischemic Stroke
Current Medicinal Chemistry Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Editorial (Hot Topic: Neuroprotection Against Stroke and CNS Injury: New Mechanisms, Targets, and Controversies)
CNS & Neurological Disorders - Drug Targets Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews